Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value |
|---|
| Revenue |
|---|
| EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
LH LH LABCORP HOLDINGS INC. FY ended Feb 23, 2026 | $334.80 | $27.15B | $32.09B | $13.95B | $2.00B | $876.50M | 32.01x | 1.95x | 14.55x |
DG DGX QUEST DIAGNOSTICS INC FY ended Feb 02, 2026 | $241.71 | $26.68B | $31.46B | $11.04B | $2.04B | $992.00M | 27.62x | 2.42x | 13.57x |
OP OPK OPKO HEALTH, INC. FY ended Jan 30, 2026 | $1.64 | $1.22B | $938.93M | $606.88M | -$136.30M | -$225.68M | -5.47x | 2.02x | — |
GH GH Guardant Health, Inc. FY ended Feb 13, 2026 | $157.95 | $21.20B | $21.60B | $982.02M | -$375.16M | -$416.28M | -47.58x | 21.58x | — |
NT NTRA Natera, Inc. FY ended Feb 20, 2026 | $319.52 | $46.06B | $45.89B | $2.31B | -$223.62M | -$208.16M | -210.21x | 19.97x | — |
EX EXAS EXACT SCIENCES CORP FY ended Feb 12, 2026 | — | — | — | $3.25B | $37.14M | -$207.95M | — | — | — |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 13.70x | 2/6 | -$685.90M | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 9.59x | 5/6 | $6.97B | $54.28 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -40.72x | 5/6 | $4.40B | $34.24 | Peer averages are not economically meaningful for this method. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
LH LH LABCORP HOLDINGS INC. FY ended Feb 23, 2026 | $334.80 | $27.15B | $32.09B | $13.95B | $2.00B | $876.50M | 32.01x | 1.95x | 14.55x |
DG DGX QUEST DIAGNOSTICS INC FY ended Feb 02, 2026 | $241.71 | $26.68B | $31.46B | $11.04B | $2.04B | $992.00M | 27.62x | 2.42x | 13.57x |
OP OPK OPKO HEALTH, INC. FY ended Jan 30, 2026 | $1.64 | $1.22B | $938.93M | $606.88M | -$136.30M | -$225.68M | -5.47x | 2.02x | — |
GH GH Guardant Health, Inc. FY ended Feb 13, 2026 | $157.95 | $21.20B | $21.60B | $982.02M | -$375.16M | -$416.28M | -47.58x | 21.58x | — |
NT NTRA Natera, Inc. FY ended Feb 20, 2026 | $319.52 | $46.06B | $45.89B | $2.31B | -$223.62M | -$208.16M | -210.21x | 19.97x | — |
EX EXAS EXACT SCIENCES CORP FY ended Feb 12, 2026 | — | — | — | $3.25B | $37.14M | -$207.95M | — | — | — |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 13.70x | 2/6 | -$685.90M | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 9.59x | 5/6 | $6.97B | $54.28 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -40.72x | 5/6 | $4.40B | $34.24 | Peer averages are not economically meaningful for this method. |
